Creative Medical Technology Holdings (CELZ) Stock Overview
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CELZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Creative Medical Technology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.71 |
| 52 Week High | US$6.90 |
| 52 Week Low | US$1.69 |
| Beta | 5.22 |
| 1 Month Change | 6.61% |
| 3 Month Change | 41.60% |
| 1 Year Change | -17.19% |
| 3 Year Change | -4.87% |
| 5 Year Change | -66.27% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CELZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 0.3% | -1.1% |
| 1Y | -17.2% | -1.2% | 15.5% |
Return vs Industry: CELZ underperformed the US Biotechs industry which returned -1.2% over the past year.
Return vs Market: CELZ underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| CELZ volatility | |
|---|---|
| CELZ Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CELZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CELZ's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Tim Warbington | www.creativemedicaltechnology.com |
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.
Creative Medical Technology Holdings, Inc. Fundamentals Summary
| CELZ fundamental statistics | |
|---|---|
| Market cap | US$8.95m |
| Earnings (TTM) | -US$5.77m |
| Revenue (TTM) | US$6.00k |
Is CELZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELZ income statement (TTM) | |
|---|---|
| Revenue | US$6.00k |
| Cost of Revenue | US$2.40k |
| Gross Profit | US$3.60k |
| Other Expenses | US$5.77m |
| Earnings | -US$5.77m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.23 |
| Gross Margin | 60.00% |
| Net Profit Margin | -96,093.48% |
| Debt/Equity Ratio | 0.2% |
How did CELZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/15 21:59 |
| End of Day Share Price | 2025/10/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Creative Medical Technology Holdings, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Roth Capital Partners |